The diagnosis and management of urothelial cell carcinoma of the bladder have been greatly influenced by recent medical, immunologic, surgical, and technological advances. One of the greatest challenges of the practicing urologist is to stay abreast with the many dynamic changes in this field. A nationally acclaimed faculty has been assembled to provide this update with presentations on topics such as diagnosis and management of non-muscle invasive bladder cancer (NMIBC); novel therapies for high-risk NMIBC including vaccines and clinical trials; immunologic approaches for the treatment of bladder cancer; technical advances in surgical treatment, bladder preservation, and reconstructive surgery. During the plenary sessions and state-of-the-art lectures, the registrants will have the opportunity to participate in question and answer sessions. In addition, an emphasis on case presentations with faculty participation will enhance the practical value of the course.

EDUCATIONAL OBJECTIVES

After participating in this activity, clinicians should be able to:

• Discuss and analyze recent clinical evidence supporting implementing immunotherapy in bladder cancer
• Recognize indications and describe best practices for surgical management, reconstruction, and bladder preservation for patients with invasive bladder cancer
• Describe new approaches to medical therapy of bladder cancer
• Describe similarities and differences of urothelial cell carcinoma of the bladder and upper urinary tract

TARGETED AUDIENCE

Urologists and Urologic Trainees (Residents and Fellows)

ACCREDITATION

The NYU Grossman School of Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.